Home Drug Codes Q Codes Q0222 · BEBTELOVIMAB
Updated July 1st, 2026

BEBTELOVIMAB Q Code: Q0222

Injection, bebtelovimab, 175 mg

Login to unlock all benchmarks
Medicare Payment Limit ?
Not published
CMS publishes none for Q3 2026
APC Payment Limit ?
Not published
CMS publishes none for Q3 2026
ASP ?
No current ASP
Not available for Q3 2026
WAC · AWP ?
$•••.••
Login to view
NDCs Crosswalked ?
1
View NDC crosswalk →

Drug & Product Overview

HCPCS Descriptor Injection, bebtelovimab, 175 mg
HCPCS Added Date February 11, 2022
Manufacturer Eli Lilly and Company
Generic Status HCPCS Discontinued

About BEBTELOVIMAB

Bebtelovimab is a medication aligned to the HCPCS Q Code: Q0222 for billing, pricing, and reimbursement purposes in the United States. It is a COVID-19 drug manufactured by Eli Lilly and Company.

Manufacturers, reach out to us to add more information.

NDC Code Information

1 NDC package is crosswalked to Q0222. Package detail is available to logged-in subscribers.

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.
Login →

BEBTELOVIMAB CPT Administration Codes

The below list of CPT codes is intended for informational purposes only and may not be exhaustive. CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved.

CPT Code Description
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
Not on the CMS JW / JZ list

CMS does not include Bebtelovimab (Q0222) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q0222. Wastage billing guide →

BEBTELOVIMAB Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Mild-to-moderate COVID-19 in adults and pediatric patients (≥12 years, ≥40 kg) at high risk for progression to severe disease when approved/authorized alternatives are not accessible or clinically appropriate

Login for BuyandBill.com Analytics

Unlock deeper insights with BuyandBill’s Comparative Report!

  • Compare ASP, WAC, and AWP across drugs.
  • Visualize Drug Price Movement Over Time
  • Tailor reports to drug class, manufacturer, or HCPCS Code.
  • Compare Biosimilar and 505(b)(2) products.

Frequently Asked Questions

Is there an available Bebtelovimab billing and coding guide?
We have not yet identified a manufacturer source of Bebtelovimab billing and coding information.
Are there any available Bebtelovimab patient assistance programs?
Our team did not identify a source for Bebtelovimab patient assistance information. Please reach out to our team if you feel that this is a mistake.
Where can I find Bebtelovimab prescribing information?
BEBTELOVIMAB prescribing information can be found at the link below: Visit Here →
Where can I find Bebtelovimab side effect information?
Information regarding BEBTELOVIMAB's side effects can be found at MedlinePlus Visit Here →
Does billing BEBTELOVIMAB require JZ/JW wastage modifiers?
CMS does not include BEBTELOVIMAB (Q0222) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q0222. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.